Carina has developed a broad-spectrum but highly targeted CAR-T cell (CNA1003). CNA1003 is targeted to a specific marker that has been found on most cancer cells but has little to no expression on healthy cells.
CNA1003 has been shown to kill a wide range of cancer cells in vitro.
By targeting a CAR-T cell at such a marker, we can develop a CAR-T therapy that has potent cancer-killing power yet results in no off-cancer side-effects.
Our researchers are currently progressing CNA1003 through the next stages of pre-clinical testing.